A team of researchers from four New York institutions have received $6 million from Stand Up to Cancer to address the low participation of Black, Indigenous and People of Color in cancer clinical trials.
City of Hope and its nursing team have achieved Magnet recognition from the American Nurses Credentialing Center.
Led by the University of California, Irvine, UC hospitals have received a $500,000 grant from NIH to transfer UC information on COVID-19 cases into the National COVID Cohort Collaborative’s centralized data resource at NIH’s National Center for Advancing Translational Sciences.
University of California Davis Comprehensive Cancer Center was named the 31st Member Institution of The National Comprehensive Cancer Network.
The Clear Your View initiative is expanding its focus to colorectal cancer to raise awareness of the important role complete biomarker testing plays in guiding initial treatment decisions for newly diagnosed advanced colorectal cancer patients.
A story in the March 19 issue of The Cancer Letter stated that the deadline for project proposals—from intramural and extramural investigators applying for clinical grade vector and cell therapy product manufacturing at Frederick National Laboratory—is in July 2021. According to updated information from NCI, the next deadline is June 15. jQuery(document).ready(function(){ jQuery('.people-thumb + p > span.has-red-100-color, .people-thumb + p >... […]
A phase III trial evaluating Keytruda (pembrolizumab) plus Lenvima (lenvatinib) in certain patients with advanced, metastatic or recurrent endometrial cancer following one prior platinum-based regimen in any setting met its dual primary endpoints of progression-free survival and overall survival.
The phase III IMpower010 study evaluating Tecentriq (atezolizumab) compared with best supportive care met its primary endpoint of disease-free survival at the interim analysis.
The phase II/III RELATIVITY-047 (CA224-047) trial evaluating the fixed-dose combination of relatlimab, an anti-LAG-3 antibody, and Opdivo (nivolumab) versus Opdivo alone in patients with previously untreated metastatic or unresectable melanoma met its primary endpoint of progression-free survival.
Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.
